Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

Parkinson’s Foundation Announces New Genetic Initiative Connecting Parkinson’s Genetic Data with Clinical Care

MIAMI & NEW YORK—March 6, 2018—The Parkinson’s Foundation today announced a new initiative offering genetic testing and counseling to Parkinson’s patients within its Center of Excellence network. The foundation is establishing a scientific and industry advisory board that will convene experts in genetics, clinical care, research, and ethics to implement this new initiative.

“For people with Parkinson’s, genetic tests are either not available, not affordable, and not covered by health insurance or offered in tandem with genetic counseling,” said John L. Lehr, CEO of the Parkinson’s Foundation. “We look to solve that by offering genetic testing, coupled with counseling in a clinical setting where doctors and patients can work together to best manage the disease.”

Three key objectives of the Parkinson’s Foundation’s Genetic Initiative are:

  1. Accelerate clinical trials: Recognizing that most people with Parkinson’s do not know their genetic status or eligibility for advanced clinical trials, the Parkinson’s Foundation will offer genetic testing at select Centers of Excellence. This initial strategy will assist in the recruitment for clinical trials of individuals with specific gene variants in LRRK2 and GBA.
  2. Unlock the potential of genetics for improved Parkinson’s care and research: Enrollment in this initiative will create the largest, active Parkinson’s disease database linking genetic status to clinical status.
  3. Empower people living with Parkinson’s: Genetic data offer insights into disease progression and symptom severity that may potentially influence clinical care and treatment decisions. 

The foundation will establish a repository of genetic data through its Parkinson’s Outcomes Project, the largest, ongoing clinical study of Parkinson’s disease to date.  The study has collected patient information on more than 10,000 individuals with Parkinson’s. The addition of genetic information to the clinical outcomes data will increase scientific knowledge and understanding of the impact of genetics in Parkinson’s.

“What makes this initiative unique is its novel approach of offering genetic testing for relevant Parkinson’s-related genes in an easily accessible, clinical environment through our network,” said James Beck, PhD, Chief Scientific Officer at the Parkinson’s Foundation. “We expect that this will accelerate enrollment in clinical trials for the next generation of treatments and help facilitate the use of genetic information to improve care and expand research.”

The Parkinson’s Foundation leads efforts to identify and disseminate new treatments and improved care through its Center of Excellence network. Each center is staffed by specialists in Parkinson’s disease treatment, delivering the highest standard of care currently available. The network includes 42 academic medical centers around the world, including 28 in the United States.

“Most people with Parkinson’s do not know their genetic status and therefore do not know if they will be eligible for the next generation of clinical trials,” said Jon Stoessl, MD, chair of the Parkinson’s Foundation Scientific Advisory Board. “With this initiative, a patient’s genetic status will be available to help inform clinical decision-making from the start, as well as track and analyze outcomes over time in a more comprehensive fashion.”

While experts estimate that 10 percent to 15 percent of all Parkinson’s cases are genetic forms of the disease, they also believe the disease is caused by a complex interaction of genetic and environmental factors. Parkinson’s Foundation-supported scientists are currently working to identify the underlying genetic mechanisms of the disease – a critical step to developing new therapies and treatments.

The foundation will convene members of its Scientific Advisory Board, patient advocates, industry and academic partners, and Center of Excellence directors in May 2018 at the annual Parkinson’s Foundation Center Leadership Conference in New Jersey. The first series of sites for implementation of the Genetic Initiative will be announced in the fall of 2018.

The idea for the Genetic Initiative sparked from discussions with Parkinson’s Foundation Scientific Advisory Board Member Roy Alcalay, MD, MS, an expert in the genetics of Parkinson’s disease and assistant professor of neurology at Columbia University, a Parkinson’s Foundation Center of Excellence.

###

About the Parkinson’s Foundation 
The Parkinson’s Foundation makes life better for people with Parkinson’s disease by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience and passion of our global Parkinson’s community. For more information, visit www.parkinson.org or call (800) 4PD-INFO (473-4636).

About Parkinson’s Disease 
Affecting nearly one million Americans and 10 million worldwide, Parkinson’s disease is the second-most common neurodegenerative disease after Alzheimer’s and is the 14th-leading cause of death in the United States. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression), as well as non-motor symptoms (e.g., depression and anxiety). There is no cure for Parkinson’s and 60,000 new cases are diagnosed each year in the United States alone.

Tuesday, March 6, 2018
The Parkinson’s Foundation 2018 Gala in New York City Tuesday, May 8, 2018
Monday, May 14, 2018

The Parkinson’s Foundation 2018 Gala was held at Cipriani 25 Broadway in New York City on Tuesday, May 8, 2018.

Parkinson’s Foundation Adds Alison Herman to its Board of Directors
Tuesday, May 8, 2018

MIAMI – May 9, 2018 – The Parkinson’s Foundation today announced the election of Alison Herman to its board of directors. Herman is senior counsel at Southern Glazer’s Wine & Spirits, a company which has generously supported Parkinson’s Foundation fundraisers.

Statement on Nuplazid Drug
Tuesday, April 10, 2018

On 4/9/18, CNN published an article on the FDA-approved drug, Nuplazid, used to treat hallucinations and psychosis in Parkinson’s disease. The article investigates FDA data showing the number of reported deaths with people taking Nuplazid. Nuplazid was approved by the FDA in 2016 and is manufactured by Acadia Pharmaceuticals.

Parkinson’s Foundation Adds John D. Thomopoulos to its Board of Directors
Monday, March 19, 2018

MIAMI & NEW YORK – March 19, 2018 – The Parkinson’s Foundation today announced the election of John D. Thomopoulos to its board of directors. Thomopoulos is a partner at Ernst & Young.

In Memory of Edythe Kay Marsa
Monday, March 12, 2018

The Parkinson’s Foundation mourns the loss of emeritus board member, Edythe (Edy) Kay Marsa. From 1993 to 2014, she was a member of the Foundation’s board of directors and served on several committees. Edy is survived by her husband William Marsa, who founded the Herbert Kay Parkinson Chapter in honor of her first husband who passed away due to complications from Parkinson’s disease.

Parkinson’s Foundation Announces New Genetic Initiative Connecting Parkinson’s Genetic Data with Clinical Care
Tuesday, March 6, 2018

MIAMI & NEW YORK—March 6, 2018—The Parkinson’s Foundation today announced a new initiative offering genetic testing and counseling to Parkinson’s patients within its Center of Excellence network.

Delegates From The Parkinson’s Community Converge On Capitol Hill To Advocate For Critical Research Funding
Monday, March 5, 2018

—2018 Parkinson’s Policy Forum Co-Sponsored by the Parkinson’s Foundation and the Michael J. Fox Foundation for Parkinson’s Research—

Parkinson’s Foundation Appoints Jena E. Abernathy to Board of Directors
Tuesday, February 27, 2018

MIAMI – February 27, 2018 –  The Parkinson’s Foundation today announced the election of Jena E. Abernathy to its board of directors.

Parkinson’s Foundation Moving Day Walks Fund Local Parkinson’s Programs in Seven Cities for Spring 2018
Friday, February 16, 2018

NEW YORK & MIAMI, FEBRUARY 16, 2018 — The Parkinson’s Foundation is proud to announce that Moving Day, A Walk for Parkinson’s, has funded more than $17 million in mission services to make life better for people living with Parkinson’s disease (PD).

Terranova’s Stephen Bittel Donates $450,000 to Parkinson’s Foundation to Support Expansion of Centers of Excellence Network
Thursday, February 1, 2018

MIAMI – February 1, 2018 – The Parkinson’s Foundation today announced that Stephen Bittel, chairman and founder of Terranova, has made a $450,000 donation to support the expansion of the foundation’s Centers o

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.